论文部分内容阅读
目的探讨ABCA3在急性白血病多药耐药中的意义,明确ABCA3是否可以作为新的急性白血病预后评估指标。方法利用ABCA3抗体,采用流式细胞技术分别测定11例正常对照和45例急性白血病患者ABCA3表达率,其中包括复发/难治急性白血病患者7例,初治高白细胞白血病患者9例,初治白血病CD34阳性表达患者15例,分析ABCA3表达临床意义。结果所有患者ABCA3表达率均为阴性。结论ABCA3是否可以作为一个新的急性白血病预后评估指标还有待于进一步研究。
Objective To investigate the significance of ABCA3 in multidrug resistance of acute leukemia and determine whether ABCA3 can be used as a new prognostic indicator of acute leukemia. Methods ABCA3 expression was detected by flow cytometry in 11 normal controls and 45 patients with acute leukemia using ABCA3 antibody, including 7 patients with relapsed / refractory acute leukemia, 9 patients with newly diagnosed leukemia, 9 patients with newly diagnosed leukemia CD34 positive expression in 15 patients, analysis of ABCA3 expression clinical significance. Results All patients were negative for ABCA3 expression. Conclusion Whether ABCA3 can be used as a new prognostic indicator of acute leukemia remains to be further studied.